Optimizing therapy with allopurinol: Factors limiting hypouricemic efficacy

American Journal of the Medical Sciences

Volumn 335, Issue 3, 2008, Pages 219-226

  Chung, Yewon ^a,b   Stocker, Sophie L ^a,c   Graham, Garry G ^a,b   Day, Richard O ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Allopurinol; Drug therapy; Drug utilization; Gout; Gout supressants

Indexed keywords

ALLOPURINOL; COLCHICINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PROBENECID; URATE; URIC ACID; XANTHINE OXIDASE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DRESS SYNDROME; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG USE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; LOW DRUG DOSE; OPTIMAL DRUG DOSE; PRESCRIPTION; RECOMMENDED DRUG DOSE; THROMBOSIS; URIC ACID BLOOD LEVEL;

EID: 40949159377     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31815acb10     Document Type: Review

References (47)

1. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology 2006;45: 1422-31.
2. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout, part I: diagnosis: report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
3. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout, part II: management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
4. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50: 937-43.
5. Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol 1988;15:1841-7.
6. Bellamy N, Brooks PM, Emmerson BT, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 1989;151:531-7.
7. Stuart RA, Gow PJ, Bellamy N, et al. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis. N Z Med J 1991;104:116-8.
8. Ferraz MB, Sato EI, Nishie IA, et al. A survey of current prescribing practices in gouty arthritis and asymptomatic hyperuricemia in San Paulo, Brazil. J Rheumatol 1994;21:374-5.
9. Vazquez-Mellado J, Espinoza J, Hernandez-Garduno A, et al. Diagnosis and treatment of gout in Mexico City: results from a physicians survey [in Spanish]. Rev Invest Clin 2003;55:621-8.
10. Fang W, Zeng X, Li M, et al. The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol 2006;33:2041-9.
11. Rozenberg S, Lang T, Laatar A, et al. Diversity of opinions on the management of gout in France: a survey of 750 rheumatologists. Rev Rheum 1996;63:255-61.
12. Schlesinger N, Moore DF, Sun JD, et al. A survey of current evaluation and treatment of gout. J Rheumatol 2006; 33:2050-2.
13. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
14. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416.
15. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
16. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32.
17. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Care Res 2004;51:321-5.
18. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
19. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
20. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
21. Perez-Ruiz F, Hernando I, Villar I, et al. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels. J Clin Rheumatol 2005;11:129-33.
22. Harrold LR, Yood RA, Mikuls TR, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 2006;65:1368-72.
23. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
24. Raebel MA, McClure DL, Simon SR, et al. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother 2006;40:386-91.
25. Graham S, Day RO, Wong H, et al. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 1996;41:299-304.
26. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxypurinol concentrations during allopurinol therapy. Br J Rheumatol 1987;26:445-9.
27. Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988;26:423-8.
28. Peterson GM, Boyle RR, Francis HW, et al. Dosage prescribing and plasma oxypurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol 1990;39:419-21.
29. Stamp L, Gow P, Sharples K, et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000;30:567-72.
30. Takada M, Okada H, Kotake T, et al. Appropriate dosing regimen of allopurinol in Japanese patients. J Clin Pharm Ther 2005;30:407-12.
31. Elion GB, Yu TF, Gutman AB, et al. Renal clearance of oxypurinol, the chief metabolite of allopurinol. Am J Med 1968; 45:69-77.
32. Gibson T, Rodgers V, Potter C, et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982;41:59-65.
33. Schepers GW. Benzbromarone therapy in hyperuricemia; comparison with allopurinol and probenecid. J Intern Med Res 1981;9:511-5.
34. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004;15:164-73.
35. Iwanaga T, Kobayashi D, Hirayama M, et al. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Disp 2005;33:1791-5.
36. Yu TF, Gutman AB. Effect of allopurinol (4-hydroxypyrazolo-(3,4-d) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964;37:885-98.
37. Williams KM, Stocker SL, McLachlan AJ, et al. Investigating pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Int Med J 2006;36:A39.
38. Reinders MK, van Roon EN, Houtman PM, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007;26:1459-65.
39. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7.
40. Puig JG, Casas EA, Ramos TH, et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol 1989;16:842-4.
41. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
42. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol [erratum appears in Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6237]. Proc Natl Acad Sci U S A 2005;102:4134-9.
43. Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int 2006;70:1694-705.
44. Geer L, Terasaki PI, Gjertson DJ. HLA frequency. In: Gjertson DW, Terasaki PI, editors. HLA 1998. Lenexa: American Society for Histocompatibility and Immunogenetics; 1998, p. 327-63.
45. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81.
46. de Klerk E, van der Heijde D, Landewe R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.
47. Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007;46:623-644.